SCHEMBL16129646

SCHEMBL16129646

COCCOCc1ccc(C(=O)Nc2ccc(-c3ccccc3)cc2)cc1NC(=O)CCl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.49
MITF O75030 1/20 0.49
ALDH1A1 P00352 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
MALT1 Q9UDY8 2/20 0.46
PTPN1 P18031 2/20 0.45
DEGS1 O15121 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
PLAU P00749 3/20 0.43
WNT3A P56704 2/20 0.43
ABCC1 P33527 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16098779 0.94 SMN1; SMN2 (0.47) SMN1; SMN2NPC1MITFALDH1A1HTT
SCHEMBL16096970 0.83 WNT3A (0.64) SMN1; SMN2MAPTWNT3A
SCHEMBL16096914 0.82 PTPN1 (0.49) SMN1; SMN2PTPN1DEGS1KDM4EMEN1
SCHEMBL16129676 0.81 HDAC8 (0.64) SMN1; SMN2NPC1MITFALDH1A1HTT
SCHEMBL16098961 0.81 WNT3A (0.52) MEN1KMT2AWNT3A
SCHEMBL16129679 0.81 HTT (0.52) SMN1; SMN2NPC1MITFALDH1A1HTT
SCHEMBL16097644 0.80 KDM4E (0.58) SMN1; SMN2NPC1MITFALDH1A1HTT
SCHEMBL16098795 0.79 ALDH1A1 (0.55) SMN1; SMN2NPC1ALDH1A1HTTRAB9A
SCHEMBL16104932 0.78 WNT3A (0.54) WNT3A
SCHEMBL16098753 0.78 WNT3A (0.54) WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160052898-A1 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 US disclosed
US-20160052898-A1 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-02-25 US disclosed
WO-2014147182-A2 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052898-A1 NOVEL COMPOUNDS AADAC, NAT1, CCNA1 SMN1; SMN2 2465/4885NPC1 933/4885MITF 306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.